Recognition that apoptosis induction is controlled by dynamic interactions between pro- and antiapoptotic members of the Bcl-2 family has led to active research programs that target antiapoptotic members of this family; the first of these, venetoclax, has been approved for treatment of chronic lymphocytic leukemia (CLL) with 17p deletion (32). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.